Literature DB >> 3260147

Recommendations for the use of Taylor series confidence intervals for estimates of vaccine efficacy.

A W Hightower, W A Orenstein, S M Martin.   

Abstract

A simple formula for calculating confidence intervals by means of a Taylor series variance approximation has been recommended for gauging the precision of estimates of vaccine efficacy. To evaluate the performance of Taylor series 95% confidence intervals for vaccine efficacy, we conducted a simulation study for commonly expected values of vaccine efficacy, risk of disease in the unvaccinated population, and sample sizes of the vaccinated and unvaccinated groups. In the first simulation, the sample size in the vaccinated group was 500 or 1000, whereas that in the unvaccinated group ranged from 10 to 1000. The confidence intervals were accurate when the sample size in the unvaccinated group was >/=50 and the risk of disease was 0.3-0.9. In contrast, the intervals were too narrow when all three of the following situations occurred: the number of unvaccinated was small (10 or 20), the true vaccine efficacy was relatively low (60% or 80%), and the risk of disease was 0.5-0.9. Furthermore, when the true vaccine efficacy was high (90% or 95%) and the disease risk in the unvaccinated was low (0.1 and 0.2), the confidence intervals were too broad, especially when the unvaccinated sample size was <50. Additional simulations with a sample size in the vaccinated group of 200 gave broad intervals for 95% vaccine efficacy (for all values of disease risk) and for 90% vaccine efficacy when the disease risk was </=0.3.

Mesh:

Substances:

Year:  1988        PMID: 3260147      PMCID: PMC2491112     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  3 in total

1.  Confidence limits to the risk ratio.

Authors:  B J Bailey
Journal:  Biometrics       Date:  1987-03       Impact factor: 2.571

2.  Field evaluation of vaccine efficacy.

Authors:  W A Orenstein; R H Bernier; T J Dondero; A R Hinman; J S Marks; K J Bart; B Sirotkin
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

3.  Statistical analyses of the relative risk.

Authors:  J J Gart
Journal:  Environ Health Perspect       Date:  1979-10       Impact factor: 9.031

  3 in total
  7 in total

1.  Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce.

Authors:  Li Tang; Diego R Hijano; Aditya H Gaur; Terrence L Geiger; Ellis J Neufeld; James M Hoffman; Randall T Hayden
Journal:  JAMA       Date:  2021-06-22       Impact factor: 56.272

2.  Molecular characterization of influenza viruses from women and infants in Sarlahi, Nepal.

Authors:  Jane Kuypers; Helen Y Chu; Charlotte A Gaydos; Joanne Katz; Subarna K Khatry; Steven C LeClerq; James M Tielsch; Mark C Steinhoff; Janet A Englund
Journal:  Diagn Microbiol Infect Dis       Date:  2018-11-15       Impact factor: 2.803

3.  SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women.

Authors:  Adeel A Butt; Hiam Chemaitelly; Abdullatif Al Khal; Peter V Coyle; Huda Saleh; Anvar H Kaleeckal; Ali Nizar Latif; Roberto Bertollini; Abdul-Badi Abou-Samra; Laith J Abu-Raddad
Journal:  J Clin Invest       Date:  2021-12-01       Impact factor: 14.808

4.  Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance.

Authors:  Andrey S Shkoda; Vladimir A Gushchin; Darya A Ogarkova; Svetlana V Stavitskaya; Olga E Orlova; Nadezhda A Kuznetsova; Elena N Keruntu; Andrei A Pochtovyi; Alexander V Pukhov; Denis A Kleymenov; Vasyli G Krzhanovsky; Daria V Vasina; Nataliya V Shkuratova; Elena V Shidlovskaya; Alexey L Gorbunov; Daria D Kustova; Evgeniya A Mazurina; Sofya R Kozlova; Alexandra V Soboleva; Igor V Grigoriev; Lyudmila L Pankratyeva; Alina S Odintsova; Elizaveta D Belyaeva; Arina A Bessonova; Lyudmila A Vasilchenko; Igor P Lupu; Ruslan R Adgamov; Artem P Tkachuk; Elizaveta A Tokarskaya; Denis Y Logunov; Alexander L Gintsburg
Journal:  Vaccines (Basel)       Date:  2022-06-13

5.  SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria.

Authors:  Georgi K Marinov; Mladen Mladenov; Antoni Rangachev; Ivailo Alexiev
Journal:  PLoS One       Date:  2022-09-09       Impact factor: 3.752

6.  Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis.

Authors:  Julien Zwang; Elizabeth A Ashley; Corine Karema; Umberto D'Alessandro; Frank Smithuis; Grant Dorsey; Bart Janssens; Mayfong Mayxay; Paul Newton; Pratap Singhasivanon; Kasia Stepniewska; Nicholas J White; François Nosten
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

7.  Prospective community programme versus parent-driven care to prevent respiratory morbidity in children following hospitalisation with severe bronchiolitis or pneumonia.

Authors:  Catherine Ann Byrnes; Adrian Trenholme; Shirley Lawrence; Harley Aish; Julie Anne Higham; Karen Hoare; Aileen Elborough; Charissa McBride; Lyndsay Le Comte; Christine McIntosh; Florina Chan Mow; Mirjana Jaksic; Russell Metcalfe; Christin Coomarasamy; William Leung; Alison Vogel; Teuila Percival; Henare Mason; Joanna Stewart
Journal:  Thorax       Date:  2020-02-24       Impact factor: 9.139

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.